



(51) International Patent Classification:

G01N 33/555 (2006.01) G01N 33/536 (2006.01)
C07K 14/00 (2006.01) C07K 14/045 (2006.01)
C07F 9/10 (2006.01) G01N 33/68 (2006.01)
C07K 17/06 (2006.01) A61K 39/385 (2006.01)
G01N 33/53 (2006.01) A61K 31/683 (2006.01)
G01N 33/531 (2006.01) A61K 38/16 (2006.01)

(21) International Application Number:

PCT/NZ2012/000029

(22) International Filing Date:

5 March 2012 (05.03.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

591514 3 March 2011 (03.03.2011) NZ

(71) Applicant (for all designated States except US): **KODE BIOTECH LIMITED** [NZ/NZ]; 19 Mount Street, Scott Laboratory Building Auckland, Univeristy of Technology, Auckland (NZ).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **HENRY, Stephen Micheal** [NZ/NZ]; 3 Lonsdale Street, Ellerslie, Auckland (NZ). **KOMARRAJU, Venkata Sarvani** [IN/NZ]; c/- 19 Mount Street, Scott Laboratory Building, Auckland (NZ).

(74) Agent: **PARKER, Stephen Robert**; Level 31, Vero Centre, 48 Shortland Street, 1010 Auckland (NZ).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: PEPTIDE-LIPID CONSTRUCTS AND THEIR USE IN A FC-FUNCTION ASSAY




FIGURE 1

(57) Abstract: The present invention discloses a method of assaying Fc-function in an immunoglobulin containing sample by contacting the sample, in the presence of a complement, with red blood cells modified to incorporate a F-S-L peptide-lipid construct. The F-S-L peptide construct comprises a functional group (F) that is a target antigen for a complement activating immunoglobulin, a spacer group (S) covalently linking F to L and a lipid group (L). The present invention further discloses a specific construct, DOPE-Ad-CMG(2)-hCMV2 (see below) where the F group is an antigen of cytomegalovirus, that is used in assaying the Fc function of an intravenous immunoglobulin (IVIG) product.